Diversified Trust Co Makes New $172,000 Investment in Xencor, Inc. (NASDAQ:XNCR)

Diversified Trust Co acquired a new stake in Xencor, Inc. (NASDAQ:XNCR) in the 1st quarter, Holdings Channel reports. The firm acquired 16,200 shares of the biopharmaceutical company’s stock, valued at approximately $172,000.

Several other hedge funds also recently modified their holdings of the stock. Exchange Traded Concepts LLC increased its stake in shares of Xencor by 23.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 1,896 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Xencor by 348.5% in the 1st quarter. GAMMA Investing LLC now owns 9,629 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 7,482 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Xencor in the 4th quarter valued at $632,000. California State Teachers Retirement System increased its stake in shares of Xencor by 12.1% in the 4th quarter. California State Teachers Retirement System now owns 59,130 shares of the biopharmaceutical company’s stock valued at $1,359,000 after acquiring an additional 6,376 shares in the last quarter. Finally, Mackenzie Financial Corp bought a new stake in shares of Xencor in the 4th quarter valued at $101,000.

Xencor Price Performance

XNCR opened at $8.30 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.89 and a quick ratio of 5.89. The company has a market capitalization of $590.71 million, a price-to-earnings ratio of -2.71 and a beta of 0.85. The firm’s fifty day moving average price is $8.80 and its two-hundred day moving average price is $13.64. Xencor, Inc. has a 1 year low of $7.16 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The firm had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $23.44 million. Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. Xencor’s revenue was up 104.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.11) earnings per share. As a group, analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

XNCR has been the subject of a number of recent research reports. Wedbush restated an “outperform” rating and set a $31.00 price target on shares of Xencor in a research note on Wednesday, April 30th. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. William Blair initiated coverage on shares of Xencor in a research note on Monday, April 21st. They set an “outperform” rating for the company. Finally, Barclays decreased their price target on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research note on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and a consensus target price of $28.00.

Insider Activity

In other Xencor news, Director Ellen Feigal sold 2,993 shares of Xencor stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 19,183 shares of the company’s stock, valued at $176,867.26. The trade was a 13.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard J. Ranieri sold 2,993 shares of Xencor stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 19,183 shares in the company, valued at $176,867.26. This represents a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 15,810 shares of company stock valued at $154,123 over the last quarter. 4.76% of the stock is owned by insiders.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.